Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
81
resultados
Última actualización
02/11/2026 [10:44:00]
Resultados 75 a 81 de 81
Resumen de: CN122351311A
The invention relates to the technical field of biology, in particular to broadleaf holly leaves, application of extracts of the broadleaf holly leaves and products for preventing or treating hypertension. The product has the following effects: the abundance of staphylococcus aureus (SA) in intestinal tracts is reduced or/and flora components are regulated; reducing the level in vivo of at least one exotoxin secreted by the SA; the expression of at least one of glutathione S-transferase and glutathione S-transferase P1 in paraventricular nucleus of hypothalamus is up-regulated. The invention also provides an application of the GSTM2/GSTP1 as a target spot in products for preventing or treating hypertension. The invention is further applied to prevention and treatment of hypertension by applying a product for up-regulating hypothalamic para-ventricular nucleus (PVN) antioxidant defense (GSTM2/GSTP1) through intestinal SA-exotoxin thereof. The invention provides a novel interventional antihypertensive target which is used for preparing novel drugs and other products for preventing and treating hypertension.
Resumen de: CN122361809A
The present invention relates to compositions and methods for identifying risk patients and modulating thrombosis conditions in cancer patients. The embodiments provided herein include a method of determining the risk of a thrombosis event in a tumor patient, the method comprising: detecting an elevated level of PPIA, PDIA3, and at least one of EIF5A, EIF4H, EIF4a3, UBE2N, UBE2L3, UBE2I, and HSP70 in a sample of a cancer patient.
Resumen de: CN122357712A
The invention provides application of an ApoL1 gene as an acute myocardial infarction diagnosis marker, and belongs to the field of gene functions and application. By detecting the expression level of APOL1 protein and mRNA in peripheral blood of an acute myocardial infarction (AMI) group and a healthy population group, it is found that the expression level of the APOL1 protein in the AMI group is 1.41 times that of the healthy population group, and the mRNA level of the APOL1 in the AMI group is 1.25 times that of the healthy population group. Compared with healthy people, the mRNA and protein levels of APOL1 in bodies of AMI patients are remarkably improved, and high expression of APOL1 is proved to be an independent risk factor of AMI and can be used as one of biomarkers for predicting AMI.
Resumen de: US20260193711A1
0000 Method of prediction of pregnancy complications associated with a high risk of pregnancy loss, such as miscarriage, stillbirth, or HELLP syndrome. Pregnant women are screened to determine the expression profile of two or more miRNAs in whole peripheral venous blood collected in the period of 10th-13th gestational week, whereas said two or more miRNAs are selected from the group miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-26a-5p, miR-130b-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p, miR-499a-5p a miR-574-3p.
Resumen de: US20260191897A1
0000 The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
Nº publicación: EP4771186A1 08/07/2026
Solicitante:
MI RNA LTD [GB]
MI:RNA LTD
Resumen de: WO2025046293A1
A method of assessing expression profiles of miRNA markers using predictive classification models to differentially diagnosing MMVD patients from healthy controls or DCM patients from healthy controls. Additionally, an assessment of the same method to discriminate pre-clinical from clinical MMVD or DCM patients. Also provided is a method of differentially diagnosing MMVD patients from DCM patients or from healthy controls.
BOPI
Sede Electrónica
